Health ❯ Healthcare ❯ Clinical Trials ❯ Cancer Research

Immunotherapy

FDA Accepts Roche’s Tecentriq for Priority Review in dMMR Stage III Colon Cancer

Approval by October 9, 2026 would establish the first immunotherapy-based adjuvant option for patients with dMMR/MSI-H stage III colon cancer.

FDA Accepts ImmunityBio Filing to Expand ANKTIVA Use in Bladder Cancer

Oncolytic Viruses Trigger T‑Cell Infiltration and Survival Signals in Early Glioblastoma Trials

Trials Show Fecal Transplants Enhance Cancer Immunotherapy, Including Longer PFS in Randomized Kidney Study

City of Hope Completes $1.5 Billion Irvine Cancer Hospital, First Patients Arrive Dec. 1